impact factor
logo
 

Treatment

 

Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis


1, 2, 3, 4, 5, 6

 

  1. Division of Rheumatology, University Hospital Zurich, Switzerland.
  2. Division of Rheumatology, University Hospital Zurich, Switzerland.
  3. Division of Rheumatology, University Hospital Zurich, Switzerland.
  4. Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland.
  5. Horten Centre for Patient-Oriented Research and Knowledge Transfer, University of Zurich, Switzerland.
  6. Division of Rheumatology, University Hospital Zurich, Switzerland. oliver.distler@usz.ch

CER9255
2016 Vol.34, N°5 ,Suppl.100
PI 0177, PF 0180
Treatment

Free to view
(click on article PDF icon to read the article)

PMID: 27494629 [PubMed]

Received: 15/01/2016
Accepted : 13/06/2016
In Press: 03/08/2016
Published: 14/10/2016

Abstract

OBJECTIVES:
Calcinosis cutis is a frequent, difficult to treat manifestation of systemic sclerosis (SSc) associated with high morbidity. The aim of this prospective, controlled, monocentric study was to assess safety and efficacy of extracorporeal shock wave therapy (ESWT) for calcinosis cutis of the finger in SSc patients.
METHODS:
A 12-week proof of concept study in which 4 SSc patients with calcinosis cutis were treated at one painful finger with high-energy, focused ESWT, in 3 sessions with one-week interval between each session. A second, untreated finger, served as control. The outcome parameters were: change in pain, change in size of calcification measured by ultrasound (US) and computed tomography (CT) and of the force by pressing the finger against a Dolorimeter.
RESULTS:
Pain was reduced (by 91% and 60%) in the treated finger in two out of four patients. There was no change in the control fingers. The size of the calcinosis in the treated finger was reduced in three (US) and four patients (CT). Inter-assessor agreement was acceptable for US volume measures (ICC=0.863).
CONCLUSIONS:
We could show promising evidence for safety and efficacy of ESWT for chronic, treatment resistant calcinosis cutis in SSc patients, thus justifying the initiation of larger multicentre controlled trials.

Rheumatology Article